Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • How big is the problem?
    • How we drive change
    • Our story
  • Featured insights
    • The latest at the Foundation
    • The latest at the Foundation
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company report cards & comparison
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • Become a catalyst
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
    • For investors
    • For companies
    • For government and policy makers
    • Events & engagements
  • Achievements so far
    • The Foundation's impact
    • The Foundation's impact
  • News
  • Our team
  • Our impact
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us
2022 Access to Medicine Index: special report

Are pharma companies addressing sexual and reproductive health access barriers for women and girls?

This Special Report, published as part of the 2022 Access to Medicine Index, highlights critical areas where companies can do more to address access issues for key healthcare products related to the sexual and reproductive health and rights (SRHR) of women and girls living in low- and middle-income countries (LMICs).

Date

18 November 2022

Download the special report

Pharmaceutical companies have a key role to play in developing products to address urgent needs in LMICs, and in expanding access to existing products in their portfolios. Such essential products include contraceptives; treatments for uterine, breast, cervical and ovarian cancers; treatments for maternal sepsis; and products targeting STIs such as HIV/AIDS.

This 14-page Special Report, available for download as an extract from the 2022 Index, examines the extent to which companies are developing new products and formulations for SRHR-related diseases and health needs – particularly looking at the gaps where further R&D is needed.

Also analysed in the report are the access strategies companies are applying in LMICs to make their products accessible through approaches such as registering their products in LMICs and employing equitable pricing strategies. The report further looks at companies' capacity building efforts and engagement in inclusive business models that are designed to reach women and girls living in LMICs.

Finally, clear 'Next Steps' are laid out as priority areas for companies and other stakeholders to address. In order to achieve the Sustainable Development Goals (SDGs) and make Universal Health Coverage a reality, action needs to focus on ensuring women and girls, no matter where they live, have access to medicines, products and services for sexual and reproductive health. 

James Hazel

Research Programme Manager

jhazel@accesstomedicinefoundation.org

Get in touch

Resource Centre

Explore our research reports and publications
Research

Spotlight on pharmaceutical companies’ actions in women’s health and SRHR

25 May 2022
Research

2022 Access to Medicine Index

15 November 2022
Research

The Methodology for the 2022 Access to Medicine Index

22 September 2021

The Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Copyright 2004 - 2022 Access to Medicine Foundation - All Rights Reserved